GLPG3970 is biologically inert in ulcerative colitis and rheumatoid arthritis, so Galapagos’s search for something better goes on.
Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.
The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.
Bristol’s new oral psoriasis option looks much better than Otezla, but competing against injectables could be tricky.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Toxicity worries send yet another Gilead/Galapagos project, ziritaxestat, to the scrapheap.